EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients
A Phase I, Open-label, Dose-escalation, Safety Study of the Combination of EPO906 and Radiation Therapy for the Treatment of Patients With Cancer
Sponsor: Novartis Pharmaceuticals
This PHASE1 trial investigates Central Nervous System Neoplasms and Head and Neck Neoplasms and is currently completed. Novartis Pharmaceuticals leads this study, which shows 10 recorded versions since 2004 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Study Description(click to expand)* To determine the maximum tolerated dose (MTD) of EPO906 administered in combination with radiation therapy and establish a recommend phase II dose.
* To evaluate the safety and toxicity profile of EPO906 when administered concurrently with radiotherapy in three disease cohorts.
* To evaluate tumor response.
* To determine the maximum tolerated dose (MTD) of EPO906 administered in combination with radiation therapy and establish a recommend phase II dose. * To evaluate the safety and toxicity profile of EPO906 when administered concurrently with radiotherapy in three disease cohorts. * To evaluate tumor response.
Status Flow
Change History
10 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE1
-
Feb 2026 — Present [monthly]
Completed PHASE1
-
Jan 2026 — Present [monthly]
Completed PHASE1
-
Jun 2025 — Feb 2026 [monthly]
Completed PHASE1
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Feb 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
For direct contact, visit the study record on ClinicalTrials.gov .